CTOR CITIUS ONCOLOGY, INC.
P/E
--
Forward P/E
10.1
Price/Sales
8.63
Beta
3.4
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Citius Oncology fourth quarter 2026 LYMPHIR unit sales grew 120% to 792 units
Citius Oncology reported preliminary results for its fiscal fourth quarter 2026, highlighting a significant acceleration in the commercial rollout of LYMPHIR....
Citius Oncology Granted Nasdaq Extension to Regain Minimum Bid Price Compliance
Citius Oncology, Inc. (CTOR) announced it has been granted an extension by the Nasdaq Stock Market to regain compliance with the minimum $1.00 bid price...